Management of Hyperprolactinemia in Children with Short Stature

Initial Diagnostic Approach

• Screen for macroprolactin when prolactin is mildly or incidentally elevated; 10–40 % of pediatric hyperprolactinemia is due to biologically inactive macroprolactin that does not require treatment. (Endocrine Society guideline) 1
• Exclude secondary causes before attributing hyperprolactinemia to a pituitary lesion: discontinue prolactin‑raising medications (e.g., antipsychotics such as risperidone, which accounted for 82 % of drug‑induced cases in a pediatric series), and evaluate for hypothyroidism and renal insufficiency. (Endocrine Society guideline) 3

Imaging Strategy

• Obtain pituitary MRI in any child with confirmed hyperprolactinemia after macroprolactin and secondary causes have been ruled out. (Endocrine Society guideline) 1
• Interpret prolactin levels in relation to tumor size: microadenomas usually present with prolactin 16–385 ng/mL, whereas macroprolactinomas typically exceed 1 400 ng/mL. (Endocrine Society guideline) 5
• When a large pituitary mass is seen but prolactin is only modestly elevated, perform serial dilutions of the serum sample to exclude the “hook effect” artifact that can falsely lower measured prolactin. (Endocrine Society guideline) 1

Medical Management

• Cabergoline is the first‑line dopamine agonist for pediatric prolactinomas; it normalizes prolactin in ~83 % of patients versus ~59 % with bromocriptine and is better tolerated. (Endocrine Society guideline) 8
• In children treated with dopamine agonists, prolactin normalizes in 60–70 % of cases, tumor size shrinks by 80–88 %, and associated symptoms such as pubertal delay and headache resolve. (Endocrine Society guideline) 8

Expected Outcomes for Growth and Puberty

• Effective treatment of hyperprolactinemia restores gonadal axis function, allowing resumption of normal pubertal development and linear growth. (Endocrine Society guideline) 8
• Normalization of menstrual cycles occurs in ~78 % of treated adolescent females, and pubertal delay resolves in the majority of pediatric patients. (Endocrine Society guideline) 8

Critical Pitfalls

• Do not assume that any elevated prolactin reflects true hyperprolactinemia; a substantial proportion of children have normal circadian profiles despite a single elevated morning value. (Endocrine Society guideline) 1
• Do not ignore modest prolactin elevations in symptomatic children, as they may indicate microprolactinomas requiring therapy. (Endocrine Society guideline) 1
• Avoid delaying treatment in symptomatic patients, because untreated hyperprolactinemia can lead to progressive pubertal delay, impaired growth, and reduced bone mineral density. (Endocrine Society guideline) 5

Table: Prolactin Levels by Tumor Size